药学学报, 2012, 47(10): 1261-1268
引用本文:
苗庆芳, 邵荣光, 甄永苏. 抗肿瘤抗体药物研究进展[J]. 药学学报, 2012, 47(10): 1261-1268.
MIAO Qing-fang, SHAO Rong-guang, ZHEN Yong-su. An overview of antibody-based cancer therapy[J]. Acta Pharmaceutica Sinica, 2012, 47(10): 1261-1268.

抗肿瘤抗体药物研究进展
苗庆芳, 邵荣光, 甄永苏*
(中国医学科学院、北京协和医学院医药生物技术研究所, 北京 100050)
摘要:

1997年以来, 抗体药物用于肿瘤治疗取得突破性的进展。据统计, 国内外已有约17种抗体药物被批准用于临床肿瘤治疗。除了一直比较成功的裸抗体, 抗体药物偶联物 (ADC) 成为抗肿瘤抗体药物研发的新热点。抗原靶标及作用机制特点决定了抗肿瘤抗体药物在临床的安全性和疗效。本文主要从肿瘤细胞杀伤机制、作为抗体靶标的肿瘤抗原、在临床的应用情况及ADC纳米粒研究方面对抗肿瘤抗体药物进行了综述。

关键词:   
An overview of antibody-based cancer therapy
Abstract:

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years.  Approximate 17 monoclonal antibodies have been approved as cancer therapeutics since 1997.  Antibody-drug conjugates (ADC) are powerful new treatment options for cancer, and naked antibodies have recently achieved remarkable success.  The safety and effectiveness of therapeutic mAbs in oncology vary depending on the nature of the target antigen and the mechanisms of tumor cell killing.  This review provides a summary of the current state of antibody-based cancer therapy, including the mechanisms of tumor cell killing by antibodies, tumor antigens as antibody targets, clinical effectiveness of antibodies in cancer patients and nanoparticles-based ADCs.

Key words:   
收稿日期:
相关功能
PDF(1313KB) Free
打印本文
0
作者相关文章